"Providence Regional Cancer System's Yelm Clinic is open for oncology and hemotology consultations every Monday. Staffed by doctors, our satellite clinic allows you to stay close to home when your appointment is with your doctor. We provide imaging and traditional oncology services like chemotherapy and an oncology lab, as well as supplemental services such as genetic counseling, patient navigators, therapeutic massage and counseling, among others."

During the past decade, Providence Regional Cancer System-Yelm conducted 130 clinical trials. In the 10-year time frame, 130 clinical trials started and 44 clinical trials were completed, i.e. on average, 33.8% percent of trials that started reached the finish line to date. In the past 5 years, 52 clinical trials started and 40 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Regional Cancer System-Yelm" #1 sponsor was "National Cancer Institute (NCI)" with 67 trials, followed by "Alliance for Clinical Trials in Oncology" with 31 trials sponsored, "SWOG Cancer Research Network" with 27 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 15 trials sponsored and "Gynecologic Oncology Group" with 15 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Regional Cancer System-Yelm" #1 collaborator was "National Cancer Institute (NCI)" with 86 trials as a collaborator, "NRG Oncology" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Providence Regional Cancer System-Yelm" are "Invasive Breast Carcinoma" (7 trials), "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Recurrent Ovarian Carcinoma" (6 trials), "Stage IV Lung Cancer AJCC v8" (6 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials). Many other conditions were trialed in "Providence Regional Cancer System-Yelm" in a lesser frequency.

Most popular intervention types in "Providence Regional Cancer System-Yelm" are "Drug" (124 trials), "Other" (87 trials), "Biological" (66 trials), "Procedure" (43 trials) and "Radiation" (13 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (38 trials), "Questionnaire Administration" (26 trials), "Biospecimen Collection" (25 trials) and "Computed Tomography" (25 trials). Other intervention names were less common.

The vast majority of trials in "Providence Regional Cancer System-Yelm" are 131 trials for "All" genders, 21 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Regional Cancer System-Yelm". undefined are not yet recruiting, 52 are recruiting, 72 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Providence Regional Cancer System-Yelm, 4 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Regional Cancer System-Yelm, 5 "Phase 1" clinical trials were conducted, 81 "Phase 2" clinical trials and 74 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".